Insulin Resistance in Your 40s and 50s: What the Early Signs Actually Tell You
02 Nov, 2026

Your energy has shifted. The weight is creeping up. The afternoon slump arrives by 3 PM even after a second coffee.
It is easy to put all of this down to age. Sometimes that is exactly what it is. But in your 40s and 50s, these changes can also sit alongside a slow shift in how your body handles glucose, and that shift usually starts long before anything shows up on a routine blood test.
This article covers what insulin resistance actually is, which early signs are worth acting on, which ones are commonly claimed but not well supported, and what the evidence says you can realistically do about it.
What insulin resistance actually is
Insulin is the hormone your pancreas releases after you eat. Its job is to move glucose out of your bloodstream and into muscle, liver and fat cells.
In insulin resistance, those tissues respond less efficiently to the same insulin signal. Your pancreas compensates by producing more. For a while this works. Your blood sugar stays normal, but only because insulin levels are running high to keep it there.
One correction to a common explanation: your cells are not “starving for glucose.” Glucose is still getting in, it just takes more insulin to get it there. Muscle glucose uptake, liver glucose output and fat tissue lipolysis are all affected to different degrees, which is why the lipid changes often appear before the glucose changes.
Metabolic syndrome is a separate, formally defined thing. Under the 2009 harmonised criteria, it means having three or more of: raised waist circumference (ethnicity-specific), triglycerides ≥150 mg/dL, HDL <40 mg/dL in men or <50 mg/dL in women, blood pressure ≥130/85 mmHg, or fasting glucose ≥100 mg/dL. Insulin resistance drives much of it, but the two are not the same diagnosis.
Why your annual check-up can look normal
This is the part most people are not told.
The Whitehall II cohort tracked over 6,500 adults and looked backwards at their blood results from up to 13 years before a diabetes diagnosis. Insulin sensitivity was already declining over that period, and it dropped sharply in roughly the last five years. Fasting glucose stayed relatively flat and then rose steeply only about three years before diagnosis.
So the sequence is: insulin sensitivity falls first, insulin output rises to compensate, and fasting glucose is the last thing to move. If fasting glucose is the only marker you check once a year, you are watching the final step of a process that has been running for years.
Note on the “decade” claim: you will often see it said that insulin resistance precedes diabetes by ten years. The honest version is that measurable changes are detectable years in advance, with the steepest deterioration in the final three to five. That is still an important window. It just is not a fixed ten-year number.
Why this matters more in India
The ICMR-INDIAB study, published in The Lancet Diabetes & Endocrinology in 2023, surveyed all 31 states and union territories. Projected to the national population for 2021, it estimated 101 million adults living with diabetes (11.4%) and 136 million with prediabetes (15.3%). It also found 351 million with abdominal obesity.
There is a second reason beyond sheer numbers. At any given BMI or waist measurement, South Asians carry more visceral and liver fat, and show more insulin resistance, than European populations. This is why Indian consensus guidelines use lower thresholds than international ones:
| Measure | Asian Indian cut-off | Standard international cut-off |
|---|---|---|
| Overweight (BMI) | 23.0–24.9 kg/m² | 25.0–29.9 kg/m² |
| Obesity (BMI) | ≥25 kg/m² | ≥30 kg/m² |
| Abdominal obesity (waist), men | >90 cm | >102 cm |
| Abdominal obesity (waist), women | >80 cm | >88 cm |
Abdominal obesity can be present in Indian adults whose BMI reads as entirely normal. A waist tape is a more useful five-second test than the weighing scale.
Signs worth paying attention to
Signs that genuinely point towards insulin resistance
- Acanthosis nigricans. Darkened, velvety thickening of the skin in the neck folds, armpits or groin. This is the most specific physical sign on this list and is directly linked to high circulating insulin. Skin tags in the same areas often accompany it.
- Rising waist circumference, particularly if your weight has not changed much. Fat redistributing to the abdomen matters more than total weight.
- High triglycerides with low HDL. This pattern, sometimes with a raised triglyceride-to-HDL ratio, tends to appear before glucose changes.
- Fatty liver on an ultrasound done for another reason. This is frequently the first objective clue, and it is commonly dismissed as incidental.
- A history of gestational diabetes or a baby over 3.5 kg. Strongly predictive of later type 2 diabetes.
- A first-degree relative with type 2 diabetes, especially diagnosed before 50.
Symptoms people notice, which are real but non-specific
Afternoon energy crashes, sugar cravings, brain fog and disturbed sleep are all frequently reported. They may well be connected to how you are handling glucose. But they also have a long list of other causes, including iron deficiency, thyroid disease, sleep apnoea, depression and simple sleep debt.
These symptoms are a good reason to get tested. They are not, on their own, evidence of insulin resistance, and no honest article should present them as diagnostic.
Where sex differences are actually supported
In women: A history of PMOS (polyendocrine metabolic ovarian syndrome, the new name adopted in May 2026 for what was previously called PCOS) is a significant risk marker. Insulin resistance is present in a majority of women with the condition, including many who are not overweight. The rename was made specifically because the old term obscured the metabolic side of the condition.
Across the menopause transition, visceral fat reliably increases and waist circumference rises. This part is well established. Whether declining oestrogen independently worsens insulin sensitivity, beyond the effect of the fat redistribution itself, is less settled. Some cohorts show an effect, others do not. What is not in dispute is that abdominal fat goes up, and abdominal fat is the relevant tissue.
In men: Central adiposity is the dominant visible marker and tends to appear earlier than in women.
Low testosterone and insulin resistance travel together. The relationship runs in both directions and visceral fat sits in the middle of it, so low testosterone should not be read as a simple cause of metabolic decline.
Four things that are worth your effort
- Get a baseline that goes beyond fasting glucose. HbA1c, a full lipid panel with triglycerides and HDL, liver enzymes, and waist circumference. Fasting insulin and HOMA-IR can be informative for tracking trends over time, but they come with a real caveat: insulin assays are not standardised across laboratories, and there is no agreed diagnostic cut-off. Treat them as a trend line measured at the same lab, not as a pass-fail test. A 2-hour OGTT remains the most sensitive way to catch early dysglycaemia.
- Build and use muscle. Skeletal muscle is where most post-meal glucose is cleared. The WHO recommends 150–300 minutes of moderate-intensity activity per week, plus muscle-strengthening work on two or more days. Resistance training improves insulin sensitivity partly through mechanisms that do not depend on insulin at all, which is why it matters even when weight does not change.
- Focus on food quality before calorie counting. Reduce ultra-processed foods and refined carbohydrates. Increase fibre from varied plant sources. In an Indian context, the practical levers are usually refined grain portions, sugar-sweetened drinks and fried snacks, rather than dietary fat.
- Protect your sleep. Experimental sleep restriction reduces insulin sensitivity in healthy adults within days, and the effect reverses with recovery sleep. The mechanism involves several pathways, not cortisol alone. Aim for 7–9 hours, and take persistent snoring with daytime sleepiness seriously, since obstructive sleep apnoea and insulin resistance frequently occur together.
When to book a clinical review
- Lab results described as “borderline” or in the prediabetes range.
- Waist above 90 cm (men) or 80 cm (women), regardless of BMI.
- Darkened skin patches in the neck, armpits or groin.
- Fatty liver reported on any scan.
- A shift in body composition that has not responded to what usually works for you.
- Persistent fatigue that rest does not fix.
- A first-degree relative with type 2 diabetes or early cardiovascular disease, plus any of the above.
- A history of PMOS, gestational diabetes, or a large-for-dates baby.
What a metabolic baseline looks like at Three 5 Reviv
Our metabolic assessments are physician-led and built around the fact that early metabolic change is a trend, not a single reading. That means measuring the things that move first, interpreting them against South Asian thresholds rather than default Western ones, and repeating them at intervals that let you see direction rather than noise.
Which specific investigations are appropriate for you is decided at your first consultation, based on your history, examination and risk profile. We do not run the same panel on everyone.
References
- Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. [A]
- Ramachandran A, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297. [A]
- Thankappan KR, et al. A peer-support lifestyle intervention for preventing type 2 diabetes in India: a cluster-randomized controlled trial of the Kerala Diabetes Prevention Program. PLoS Med. 2018;15(6):e1002575. [A — negative for primary outcome]
- Diabetes Prevention Program Research Group. 21-year follow-up outcomes. Lancet Diabetes Endocrinol. 2025. [A]
- Anjana RM, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474–489. [B]
- Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215–2221. [B]
- Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026. [C]
- Misra A, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians. J Assoc Physicians India. 2009;57:163–170. [C]
- Alberti KGMM, et al. Harmonizing the metabolic syndrome: a joint interim statement. Circulation. 2009;120(16):1640–1645. [C]
- World Health Organization. WHO Guidelines on Physical Activity and Sedentary Behaviour. Geneva: WHO; 2020. [C]
Evidence grade key: A = randomised controlled trial or meta-analysis of RCTs; B = large prospective cohort or national cross-sectional survey; C = consensus guideline or expert statement.
Recent Blogs
Availability
Monday-Sunday 7AM to 8PM
Three 5 Reviv Private Limited
17/1, Cowley Brown Road,
RS Puram West,
Coimbatore - 641 002
Tamil Nadu, India
© 2026 Three 5 Reviv
Designed and Developed by Appac Mediatech Pvt Ltd

